ASTRAZENECA PLCAZNEarnings & Financial Report
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
AZN Q2 FY2025 Key Financial Metrics
Revenue
$14.5B
Gross Profit
$12.0B
Operating Profit
$3.5B
Net Profit
$2.4B
Gross Margin
82.9%
Operating Margin
24.3%
Net Margin
16.9%
YoY Growth
11.7%
EPS
$1.57
ASTRAZENECA PLC Q2 FY2025 Financial Summary
ASTRAZENECA PLC reported revenue of $14.5B (up 11.7% YoY) for Q2 FY2025, with a net profit of $2.4B (up 27.0% YoY) (16.9% margin). Cost of goods sold was $2.5B, operating expenses totaled $8.5B.
Key Financial Metrics
| Total Revenue | $14.5B |
|---|---|
| Net Profit | $2.4B |
| Gross Margin | 82.9% |
| Operating Margin | 24.3% |
| Report Period | Q2 FY2025 |
ASTRAZENECA PLC Quarterly Revenue & Net Profit History
ASTRAZENECA PLC results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $14.5B | +11.7% | $2.4B | 16.9% |
| Q2 FY2024 | $12.9B | +13.3% | $1.9B | 14.9% |
| Q2 FY2023 | $11.4B | +6.0% | $1.8B | 15.9% |
| Q2 FY2022 | $10.8B | +31.0% | $360.0M | 3.3% |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $10.77B | $11.42B | $12.94B | $14.46B |
| YoY Growth | 31.0% | 6.0% | 13.3% | 11.7% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $96.58B | $96.54B | $104.34B | $112.42B |
| Liabilities | $60.63B | $59.13B | $64.74B | $67.61B |
| Equity | $35.95B | $37.42B | $39.60B | $44.81B |